<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01565096</url>
  </required_header>
  <id_info>
    <org_study_id>ikfe-Vilda-001</org_study_id>
    <secondary_id>2011-004286-32</secondary_id>
    <secondary_id>CLAF237ADE06T</secondary_id>
    <nct_id>NCT01565096</nct_id>
  </id_info>
  <brief_title>Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy</brief_title>
  <official_title>Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ikfe-CRO GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>IKFE Institute for Clinical Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ikfe-CRO GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot-study is to investigate the effect of Vildagliptin in comparison to
      glimepiride on beta cell function and the cardiovascular risk profile in patients previously
      treated with Metformin monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial increase in intact proinsulin levels in patient treated with Vildagliptin and Metformin compared to intact proinsulin levels in patients treated with Glimepiride and Metformin (Area under the curve 0-300 min)</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting intact proinsulin levels</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Max postprandial intact proinsulin levels</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal endothelial response to flicker light stimulation</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 24h systolic and diastolic blood pressure</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte deformability</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E-selectin</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemic events</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug related adverse events</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Diabetes Mellitus Type II</condition>
  <arm_group>
    <arm_group_label>Vildagliptin plus Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin (1000 mg BID) + Vildagliptin 50 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepirid plus Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin (1000 mg BID) + Glimepiride (individual dosage)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1000 mg BID</description>
    <arm_group_label>Vildagliptin plus Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 1000 mg BID</description>
    <arm_group_label>Glimepirid plus Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Vildagliptin 50 mg twice daily</description>
    <arm_group_label>Vildagliptin plus Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Glimepiride at individual dose</description>
    <arm_group_label>Glimepirid plus Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes mellitus type 2

          -  HbA1c &gt; 6.5%* ≤ 9.5%

             * NOTE: Patients with cardiovascular preconditions (Coronary Heart Disease or Myocard
             Infarction) require an HbA1c &gt; 7.0% ≤ 9.5%

          -  Treatment with Metformin at maximal or maximal tolerated dosage, stable for at least 3
             months with indication for treatment with an additional medication as judged by the
             investigator

          -  Age 30 - 80 years

          -  Patient consents that his/her family physician will be informed of trial participation

        Exclusion Criteria:

          -  Pre-treatment with insulin, peroxisome proliferator activated receptor (PPAR) gamma
             agonists or other oral antidiabetic treatments (except Metformin) within the last
             three months

          -  History of type-1-diabetes

          -  Fasting blood glucose &gt;240mg/dl

          -  Uncontrolled hypertension (systolic blood pressure &gt;160 and/or diastolic blood
             pressure &gt;90)

          -  Anamnestic history of acute infections

          -  Anamnestic history of epilepsy

          -  Anamnestic history of hypersensitivity to the study drugs or to drugs with similar
             chemical structures

          -  History of severe or multiple allergies

          -  Hereditary galactose intolerance, lapp-lactase defect or glucose-galactose
             mal-absorption

          -  Treatment with any other investigational drug within 3 months before trial entry

          -  Pregnant or lactating women

          -  Sexually active woman of childbearing age not practicing a highly effective method of
             birth control as defined as those which result in a low failure rate (i.e. less than
             1% per year) when used consistently and correctly such as implants, injectables,
             combined oral contraceptives, hormonal intrauterine devices, sexual abstinence or
             vasectomized partner

          -  Progressive fatal disease

          -  History of drug or alcohol abuse in the past 2 years

          -  State after kidney transplantation

          -  Serum potassium &gt; 5.5 mmol/L

          -  Acute myocardial infarction, open heart surgery or cerebral event (stroke/transient
             ischemic attack) within the previous 6 months

          -  Any elective surgery during study participation

          -  Have had more than one unexplained episode of severe hypoglycemia (defined as
             requiring assistance of another person due to disabling hypoglycemia) within 6 months
             prior to screening visit

          -  History of pancreatitis

          -  Anamnestic history of dehydration, diabetic precoma or diabetic ketoacidosis

          -  Acute or scheduled investigation with iodine containing radiopaque material

          -  Uncontrolled unstable angina pectoris

          -  Anamnestic history of pericarditis, myocarditis, endocarditis, hemodynamic relevant
             aortic stenosis, aortic aneurysm or heart insufficiency NYHA III or IV

          -  Anamnestic recent pulmonary embolism

          -  History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT
             and/or ASAT &gt; 3 times the normal reference range), renal (GFR &lt; 60 ml), neurological,
             psychiatric and/or hematological disease as judged by the investigator

          -  Lack of compliance or other similar reason that, according to investigator, precludes
             satisfactory participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Forst, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ikfe GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Forst, Prof. Dr.</last_name>
    <phone>+49 6131 576 36 16</phone>
    <email>thomasf@ikfe.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Swantje Anders</last_name>
    <phone>+49 6131 327 90 22</phone>
    <email>s.anders@ikfe-cro.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ikfe GmbH</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Forst, Prof., MD</last_name>
      <phone>+49 6131 576 36 16</phone>
      <email>thomasf@ikfe.de</email>
    </contact>
    <contact_backup>
      <last_name>Swantje Anders</last_name>
      <phone>+49 6131 327 90 22</phone>
      <email>s.anders@ikfe-cro.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2012</study_first_posted>
  <last_update_submitted>March 26, 2012</last_update_submitted>
  <last_update_submitted_qc>March 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

